vs
B&G Foods, Inc.（BGS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
B&G Foods, Inc.的季度营收约是Orthofix Medical Inc.的2.0倍（$439.3M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -4.4%，领先3.3%），Orthofix Medical Inc.同比增速更快（2.0% vs -4.7%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-70.7M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -12.8%）
B&G Foods是总部位于美国新泽西州帕西帕尼的品牌食品控股企业，创立于1996年，成立初衷是收购1889年诞生于曼哈顿的酸黄瓜、调味酱及调味品生产商Bloch & Guggenheimer，如今在北美食品领域拥有众多知名品牌。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
BGS vs OFIX — 直观对比
营收规模更大
BGS
是对方的2.0倍
$219.9M
营收增速更快
OFIX
高出6.7%
-4.7%
净利率更高
OFIX
高出3.3%
-4.4%
自由现金流更多
OFIX
多$87.5M
$-70.7M
两年增速更快
OFIX
近两年复合增速
-12.8%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $439.3M | $219.9M |
| 净利润 | $-19.1M | $-2.2M |
| 毛利率 | 22.5% | 71.1% |
| 营业利润率 | 2.5% | 0.2% |
| 净利率 | -4.4% | -1.0% |
| 营收同比 | -4.7% | 2.0% |
| 净利润同比 | -356.5% | 92.4% |
| 每股收益（稀释后） | $-0.24 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGSOFIX
| Q4 25 | — | $219.9M | ||
| Q3 25 | $439.3M | $205.6M | ||
| Q2 25 | $424.4M | $203.1M | ||
| Q1 25 | $425.4M | $193.6M | ||
| Q4 24 | $551.6M | $215.7M | ||
| Q3 24 | $461.1M | $196.6M | ||
| Q2 24 | $444.6M | $198.6M | ||
| Q1 24 | $475.2M | $188.6M |
净利润BGSOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-19.1M | $-22.8M | ||
| Q2 25 | $-9.8M | $-14.1M | ||
| Q1 25 | $835.0K | $-53.1M | ||
| Q4 24 | $-222.4M | $-29.1M | ||
| Q3 24 | $7.5M | $-27.4M | ||
| Q2 24 | $3.9M | $-33.4M | ||
| Q1 24 | $-40.2M | $-36.0M |
毛利率BGSOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | 22.5% | 72.2% | ||
| Q2 25 | 20.5% | 68.7% | ||
| Q1 25 | 21.2% | 62.8% | ||
| Q4 24 | 21.5% | 69.0% | ||
| Q3 24 | 22.2% | 68.7% | ||
| Q2 24 | 20.7% | 67.8% | ||
| Q1 24 | 22.9% | 67.5% |
营业利润率BGSOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | 2.5% | -8.3% | ||
| Q2 25 | 5.2% | -7.9% | ||
| Q1 25 | 8.4% | -25.2% | ||
| Q4 24 | -46.6% | -5.3% | ||
| Q3 24 | 11.1% | -9.6% | ||
| Q2 24 | 9.9% | -12.5% | ||
| Q1 24 | -3.3% | -15.6% |
净利率BGSOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | -4.4% | -11.1% | ||
| Q2 25 | -2.3% | -6.9% | ||
| Q1 25 | 0.2% | -27.4% | ||
| Q4 24 | -40.3% | -13.5% | ||
| Q3 24 | 1.6% | -13.9% | ||
| Q2 24 | 0.9% | -16.8% | ||
| Q1 24 | -8.5% | -19.1% |
每股收益（稀释后）BGSOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $-0.24 | $-0.57 | ||
| Q2 25 | $-0.12 | $-0.36 | ||
| Q1 25 | $0.01 | $-1.35 | ||
| Q4 24 | $-2.81 | $-0.76 | ||
| Q3 24 | $0.09 | $-0.71 | ||
| Q2 24 | $0.05 | $-0.88 | ||
| Q1 24 | $-0.51 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $60.9M | $82.0M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $470.7M | $450.0M |
| 总资产 | $2.9B | $850.6M |
| 负债/权益比越低杠杆越低 | 4.30× | — |
8季度趋势，按日历期对齐
现金及短期投资BGSOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | $60.9M | $62.9M | ||
| Q2 25 | $54.1M | $65.6M | ||
| Q1 25 | $61.2M | $58.0M | ||
| Q4 24 | $50.6M | $83.2M | ||
| Q3 24 | $54.7M | $30.1M | ||
| Q2 24 | $40.3M | $26.4M | ||
| Q1 24 | $42.5M | $27.0M |
总债务BGSOFIX
| Q4 25 | — | — | ||
| Q3 25 | $2.0B | $157.2M | ||
| Q2 25 | $2.0B | $157.0M | ||
| Q1 25 | $2.0B | $156.9M | ||
| Q4 24 | $2.0B | $157.0M | ||
| Q3 24 | $2.1B | $118.5M | ||
| Q2 24 | $2.0B | $118.0M | ||
| Q1 24 | $2.0B | $118.2M |
股东权益BGSOFIX
| Q4 25 | — | $450.0M | ||
| Q3 25 | $470.7M | $442.5M | ||
| Q2 25 | $501.4M | $458.3M | ||
| Q1 25 | $513.1M | $458.3M | ||
| Q4 24 | $524.8M | $503.1M | ||
| Q3 24 | $755.3M | $525.9M | ||
| Q2 24 | $765.0M | $546.0M | ||
| Q1 24 | $781.2M | $570.3M |
总资产BGSOFIX
| Q4 25 | — | $850.6M | ||
| Q3 25 | $2.9B | $832.6M | ||
| Q2 25 | $2.9B | $837.2M | ||
| Q1 25 | $3.0B | $823.1M | ||
| Q4 24 | $3.0B | $893.3M | ||
| Q3 24 | $3.4B | $867.9M | ||
| Q2 24 | $3.4B | $882.0M | ||
| Q1 24 | $3.4B | $906.0M |
负债/权益比BGSOFIX
| Q4 25 | — | — | ||
| Q3 25 | 4.30× | 0.36× | ||
| Q2 25 | 3.97× | 0.34× | ||
| Q1 25 | 3.91× | 0.34× | ||
| Q4 24 | 3.85× | 0.31× | ||
| Q3 24 | 2.75× | 0.23× | ||
| Q2 24 | 2.67× | 0.22× | ||
| Q1 24 | 2.61× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-64.6M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-70.7M | $16.8M |
| 自由现金流率自由现金流/营收 | -16.1% | 7.6% |
| 资本支出强度资本支出/营收 | 1.4% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $54.8M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流BGSOFIX
| Q4 25 | — | $27.7M | ||
| Q3 25 | $-64.6M | $12.4M | ||
| Q2 25 | $17.8M | $11.6M | ||
| Q1 25 | $52.7M | $-18.4M | ||
| Q4 24 | $80.3M | $23.7M | ||
| Q3 24 | $4.2M | $11.7M | ||
| Q2 24 | $11.3M | $9.0M | ||
| Q1 24 | $35.1M | $-18.6M |
自由现金流BGSOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | $-70.7M | $2.5M | ||
| Q2 25 | $11.5M | $4.5M | ||
| Q1 25 | $42.4M | $-25.1M | ||
| Q4 24 | $71.7M | $15.2M | ||
| Q3 24 | $-679.0K | $6.3M | ||
| Q2 24 | $5.2M | $-360.0K | ||
| Q1 24 | $27.5M | $-29.1M |
自由现金流率BGSOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | -16.1% | 1.2% | ||
| Q2 25 | 2.7% | 2.2% | ||
| Q1 25 | 10.0% | -13.0% | ||
| Q4 24 | 13.0% | 7.0% | ||
| Q3 24 | -0.1% | 3.2% | ||
| Q2 24 | 1.2% | -0.2% | ||
| Q1 24 | 5.8% | -15.4% |
资本支出强度BGSOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | 1.4% | 4.8% | ||
| Q2 25 | 1.5% | 3.5% | ||
| Q1 25 | 2.4% | 3.5% | ||
| Q4 24 | 1.6% | 4.0% | ||
| Q3 24 | 1.0% | 2.7% | ||
| Q2 24 | 1.4% | 4.7% | ||
| Q1 24 | 1.6% | 5.6% |
现金转化率BGSOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 63.17× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.56× | — | ||
| Q2 24 | 2.87× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGS
| Specialty Segment | $150.5M | 34% |
| Meals Segment | $110.0M | 25% |
| Spices And Flavor Solutions Segment | $101.4M | 23% |
| Frozen And Vegetables Segment | $77.4M | 18% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
